Asbury United Methodist Church
Sharing Christ's Love Generation to Generation

Bayers bioequivalence research comparing Adalat XL to Mylan-Nifedipine Extended Launch flawed.

Marvin C. Meyer, Ph.D., Professor Emeritus, University of Tennessee at consultant and Memphis to Mylan, provides submitted a formal rebuttal to the International Journal of Clinical Pharmacology and Therapeutics entitled Important Questions Regarding the Validity of the Bayer Research Survey of ‘Differences in bioavailability between 60 mg of nifedipine osmotic push-draw systems after fasted and fed administration.’ Peer review and publication is definitely pending. Provided the flaws in the Bayer-sponsored research, Mylan encourages healthcare suppliers to reject its therapeutically inaccurate conclusions and become assured that Mylan’s item meets most of Health Canada’s stringent suggestions for bioequivalence.. Bayer’s bioequivalence research comparing Adalat XL to Mylan-Nifedipine Extended Launch flawed, says Mylan Mylan today reported that it offers identified multiple flaws within a purported bioequivalence research sponsored by Bayer Inc.Related StoriesWHO focused on helping Nepal deliver healthcare to its citizens, says WHO South-East Asia Regional DirectorNHS hourglass framework holds back development of support workforceNeurological tests accessibility and affordability: an interview with Dr Joseph Higgins If Congress truly wants to reform our health care system, Senators and Representatives must response to their constituents you need to include comprehensive medical liability reform to help make the system more available and affordable for all individuals, Stinson said. A National Quorum poll of 1 1,009 adults was conducted in October 2009. According to the poll, 62 percent of these surveyed responded that they need their elected representatives in Washington to aid national comprehensive medical liability reform legislation, and 69 percent believe that these liability reforms should be included in any health care reform legislation passed by Congress.